21 Results for "

VEGF-A expression

" in MedChemExpress (MCE) Product Catalog:
Products (21)

21 Results for "VEGF-A expression" in MCE Product Catalog:

34
34 Publications Verification
Cat. No.: HY-B1788
CAS No.: 81-24-3
Synonyms: N-Choloyltaurine
Taurocholic acid (N-Choloyltaurine) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid has immunoregulation effect .
loading...
    loading...
34
34 Publications Verification
Cat. No.: HY-N0545
CAS No.: 145-42-6
Synonyms: Sodium taurocholate; N-Choloyltaurine sodium
Taurocholic acid sodium (Sodium taurocholate) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid sodium has immunoregulation effect .
loading...
    loading...
34
34 Publications Verification
Cat. No.: HY-B1131
CAS No.: 345909-26-4
Synonyms: Sodium taurocholate hydrate; N-Choloyltaurine sodium salt hydrate
Taurocholic acid (N-Choloyltaurine) sodium salt hydrate has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid sodium salt hydrate has immunoregulation effect .
loading...
    loading...
13
13 Cited Publications
Cat. No.: HY-117661
CAS No.: 1818389-84-2
Target:  

SRPK VEGFR

Research Areas:  

Cardiovascular Disease Cancer

SPHINX31 is a potent and selective SRPK1 inhibitor, with an IC50 of 5.9 nM. SPHINX31 inhibits phosphorylation of serine/arginine-rich splicing factor 1 (SRSF1). SPHINX31 also decreases the mRNA expression of pro-angiogenic VEGF-A165a isoform. SPHINX31 can be used to research neovascular eye disease .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-N2187
CAS No.: 43043-74-9
Deoxyshikonin increases the expression of VEGF-C and VEGF-A mRNA in HMVEC-dLy, promotes HIF-1α and HIF-1β subunit interaction and binds to specific DNA sequences targeted by HIF. Deoxyshikonin inhibited colorectal cancer (CRC) through the PI3K/Akt/mTOR pathway. Deoxyshikonin has proangiogenesis effect and antitumor activity. Deoxyshikonin is an antibacterial agent against methicillin-resistant S. aureus (MRSA) and S. pneumonia (MIC=17 μg/mL) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P10284
CAS No.: 853248-13-2
S7 is an inhibitory polypeptide targeting IL-6R, which specifically binds to IL-6R and its A chain (gp80/IL-6RA) to block its signal transduction. S7 inhibits IL-6-mediated anti-apoptosis (apoptosis), angiogenesis and the expression of VEGF-A, blocks related survival signaling pathways, and enhances the sensitivity of cancer cells to chemotherapeutic drugs. S7 can be applied to the research of related diseases such as cervical cancer, multiple myeloma, Kaposi's sarcoma, prostate cancer and basal cell carcinoma .
loading...
    loading...
Cat. No.: HY-P991097
Synonyms: PM-8002; BNT-327

Target:  

VEGFR PD-1/PD-L1

Research Areas:  

Cancer

Pumitamig (PM-8002, BNT-327) is a bispecific antibody targeting PD-L1 and VEGF-A, with immune activation and anti-angiogenic activities. By binding to PD-L1, Pumitamig restores the function of effector T cells, while neutralizing VEGF-A in the tumor microenvironment to reverse its inhibition on the infiltration and activation of immune cells and normalize tumor blood vessels. Pumitamig can also be combined with various ADCs targeting TROP2, B7H3, HER2, HER3 for the research of advanced/metastatic solid tumors, including non-small cell lung cancer, ovarian cancer, triple-negative breast cancer, cervical cancer, etc. Pumitamig also exhibits potential efficacy in "cold" tumors with low PD-L1 expression that are insensitive to immunotherapy .
loading...
    loading...
Cat. No.: HY-115746
CAS No.: 1568-83-8
Purity:  99.78%
Synonyms: DMBPA
Research Areas:  

Cancer

Dimethyl-bisphenol A (DMBPA) is a potent HIF-1α inhibitor. Dimethyl-bisphenol A can decrease Vegfa mRNA expression .
loading...
    loading...
Cat. No.: HY-N0545R
CAS No.: 145-42-6
Synonyms: Sodium taurocholate (Standard); N-Choloyltaurine sodium (Standard)
Taurocholic acid (sodium) (Standard) is the analytical standard of Taurocholic acid (sodium). This product is intended for research and analytical applications. Taurocholic acid sodium (Sodium taurocholate) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid sodium has immunoregulation effect .
loading...
    loading...
Cat. No.: HY-P3990
CAS No.: 1029227-48-2
Target:  

VEGFR Autophagy Apoptosis

Research Areas:  

Cancer

Coibamide A, an N-methyl-stabilized cytotoxic depsipeptide, shows potent antiproliferative activity. Coibamide A induces autophagosome accumulation via an mTOR-independent mechanism. Coibamide A induces apoptosis. Coibamide A inhibits VEGFA/VEGFR2 expression and suppresses tumor growth in glioblastoma xenografts .
loading...
    loading...
Cat. No.: HY-W653842
CAS No.: 1351996-69-4
Synonyms: Sodium taurocholate-d8 (Standard); N-Choloyltaurine-d8 sodium
Taurocholic acid-d8 (sodium) is deuterium labeled Taurocholic acid (sodium). Taurocholic acid sodium (Sodium taurocholate) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid sodium has immunoregulation effect .
loading...
    loading...
Cat. No.: HY-B1788R
CAS No.: 81-24-3
Synonyms: N-Choloyltaurine (Standard)
Taurocholic acid (Standard) is the analytical standard of Taurocholic acid. This product is intended for research and analytical applications. Taurocholic acid (N-Choloyltaurine) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid has immunoregulation effect .
loading...
    loading...
Cat. No.: HY-101931
CAS No.: 1637443-98-1
Purity:  99.26%
Target:  

VEGFR

Research Areas:  

Cancer

hVEGF-IN-1, a quinazoline derivative, could specifically bind to the G-rich sequence in the internal ribosome entry site A (IRES-A) and destabilize the G-quadruplex structure. hVEGF-IN-1 binds to the IRES-A (WT) with a Kd of 0.928 μM in SPR experiments. hVEGF-IN-1 could hinder tumor cells migration and repress tumor growth by decreasing VEGF-A protein expression .
loading...
    loading...
Cat. No.: HY-W653893
Taurocholic acid-d5 (sodium) is deuterium labeled Taurocholic acid (sodium). Taurocholic acid sodium (Sodium taurocholate) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid sodium has immunoregulation effect .
loading...
    loading...
Cat. No.: HY-B1788S2
CAS No.: 2044276-13-1
Synonyms: N-Choloyltaurine-d5
Taurocholic acid-d5 (Taurocholic Acid-d5) is deuterium labeled Taurocholic acid. Taurocholic acid (N-Choloyltaurine) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid has immunoregulation effect .
loading...
    loading...
Cat. No.: HY-163760
CAS No.: 2667585-44-4
Target:  

HuR MMP

Research Areas:  

Cancer

ZM-32 is an inhibitor for human antigen R (HuR), that downregulates the expression of VEGF-A and MMP9, and thus inhibits breast cancer tumor angiogenesis. ZM-32 exhibits broad-spectrum anti-proliferative effects in a variety of cancer cell lines, and exhibits antitumor efficacy against MDA-MB-231 in mouse models .
loading...
    loading...
Cat. No.: HY-176805
CAS No.: 2665700-67-2
Target:  

MicroRNA VEGFR

Research Areas:  

Cardiovascular Disease

TGP-377 is a potent miR-377 inhibitor that specifically and effectively enhances VEGFA expression by targeting the non-coding microRNA that regulates VEGFA expression .
loading...
    loading...
Cat. No.: HY-168560
Target:  

MMP

Research Areas:  

Cancer

MMP Inhibitor 4 (compound 4 B) is a potent MMP inhibitor. MMP Inhibitor 4 shows antiproliferative activity. MMP Inhibitor 4 induces cell cycle arrest at subG1 phase. MMP Inhibitor 4 decreases the mRNA expression of MMP2, MMP9 and VEGFA .
loading...
    loading...
Cat. No.: HY-N0545S2
Synonyms: Sodium taurocholate-d4-1 ; N-Choloyltaurine-d4-1 sodium
Taurocholic acid-d4-1 sodium (Sodium taurocholate-d4-1) is the deuterium labeled Taurocholic acid sodium (HY-N0545). Taurocholic acid sodium (Sodium taurocholate) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid sodium has immunoregulation effect .
loading...
    loading...
Cat. No.: HY-P992518

Target:  

VEGFR PD-1/PD-L1

Research Areas:  

Cancer

Pumitamig (Mouse IgG2a) is the Mouse IgG2a control antibody for Pumitamig (HY-P991097). Pumitamig (PM-8002, BNT-327) is a bispecific antibody targeting PD-L1 and VEGF-A, with immune activation and anti-angiogenic activities. By binding to PD-L1, Pumitamig restores the function of effector T cells, while neutralizing VEGF-A in the tumor microenvironment to reverse its inhibition on the infiltration and activation of immune cells and normalize tumor blood vessels. Pumitamig can also be combined with various ADCs targeting TROP2, B7H3, HER2, HER3 for the research of advanced/metastatic solid tumors, including non-small cell lung cancer, ovarian cancer, triple-negative breast cancer, cervical cancer, etc. Pumitamig also exhibits potential efficacy in "cold" tumors with low PD-L1 expression that are insensitive to immunotherapy .
loading...
    loading...